LoginMy Member Benefitsarchivesresearchyour teamabout usFAQLog out
×
Hot Topics
Share
Access Your Profit Alerts

biotech bubble

Article Index

Why Biotech Stocks Are Down This Week

By , Associate Editor, Money Morning • @KyleAndersonMM -

biotech stocks

Investors are again worried about a biotech bubble as biotech stocks take another big hit this week.

Since April 23, the Nasdaq Biotechnology Index has dropped 6.8%. During the same time, the S&P Biotechnology Industry Index is down 8.5%.

But this is not a biotech bubble we're seeing...

Sell-Off in Biotech Stocks Making for Attractive Entry Points

By , Associate Editor, Money Morning • @JimBach22 -

U.S. stock futures

Last week on our roundup of the 2015 top stocks to invest in, we highlighted biotech stocks for their explosive growth in 2015 and their continued potential.

And while biotech stocks got creamed this past week. They're still among the best investments for 2015.

Just look at our top stocks to invest in for 2015, which still features a few biotech stocks as our best performers...

Is This a Biotech Bubble?

By , Associate Editor, Money Morning • @KyleAndersonMM -

biotech bubble

Wall Street pundits are claiming we are on the precipice of a biotech bubble because biotechnology stocks have been soaring. The Nasdaq Biotechnology Index has climbed 44% in the last year. The Nasdaq Composite and S&P 500 have climbed just 9% and 11% in the same time.

But it's the last week that has traders panicked about "bubble" territory.

From March 20 through March 26, the Nasdaq biotech index dipped 7%. The S&P biotech index dropped almost 11%.

These tremors could signify a correction in the coming months - but make no mistake - the "bubble" is not about to burst on biotech stocks...

There Is No Biotech Bubble; Here's the Real Story

By , Biotech Investing Specialist, Money Morning -

Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

But they're wrong; the market is simply in a period of adjustment.

The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

The problem with that argument is, these analysts are using a mass of technical indicators to support it. Anyone who's followed start-up biotechs knows that's a fool's errand.

Today's Markets
DJIA 110.59 (0.43%) 25,669.32
NASDAQ 9.80 (0.13%) 7,816.33
S&P 9.44 (0.33%) 2,850.13